Alzamend Neuro financials
$1.82+5.20%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Apr 30 | FY25 Apr 30 | FY24 Apr 30 | FY23 Apr 30 | FY22 Apr 30 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$8.8M | -$4.5M | -$9.9M | -$14.9M | -$12.3M |
| Net income | -$8.8M | -$5.1M | -$9.9M | -$14.9M | -$12.4M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-2.63 | $-11.32 | $-14.70 | $-206.01 | $-189.00 |
| EBITDA | -$8.7M | -$4.4M | -$9.9M | -$14.8M | -$12.3M |
| Operating cash flow | -$8.1M | -$6.6M | -$8.3M | -$8.9M | -$6.6M |
| Free cash flow | -$8.1M | -$6.9M | -$8.4M | -$8.9M | -$6.7M |
| Diluted shares | 3.3M | 0.5M | 0.7M | 0.1M | 0.1M |
Balance sheet
| Period end | Apr 30 | Apr 30 | Apr 30 | Apr 30 | Apr 30 |
|---|---|---|---|---|---|
| Cash & equivalents | $710.7K | $3.9M | $376.0K | $5.1M | $14.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $300.7K | $0.00 | $0.00 |
| Total assets | $2.1M | $4.6M | $631.6K | $5.9M | $14.5M |
| Total liabilities | $1.3M | $634.8K | $3.2M | $2.9M | $1.2M |
| Shareholders' equity | $733.2K | $4.0M | -$2.6M | $3.0M | $13.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology